(Stroke. 2001;32:17.)
© 2001 American Heart Association, Inc.
Original Contributions |
From the Department of Neurology, Klinikum Großhadern, Ludwig-Maximilians-Universität München.
Correspondence to Dr Martin Dichgans, Department of Neurology, Klinikum Großhadern, Marchioninstr 15, 81377 München, Germany. E-mail mdichgans{at}brain.nefo.med-uni-muenchen.de
Background and PurposeCerebral autosomal dominant arteriopathy with subcortical infarcts and leukencephalopathy (CADASIL) is a hereditary angiopathy caused by mutations in Notch3. Cerebral microvessels show an accumulation of granular osmiophilic material in the vicinity of degenerating vascular smooth muscle cells. To study cerebrovascular function in CADASIL, we performed measurements on cerebral hemodynamics by using transcranial Doppler sonography.
MethodsMiddle cerebral artery (MCA) mean blood flow velocity (MFV), cerebrovascular CO2 reactivity, and the resistance index were measured by bilateral transcranial Doppler sonography in 29 CADASIL individuals (mean age, 49.0±2.4 years) and an equal number of age- and sex-matched control subjects.
ResultsCompared with control subjects, CO2 reactivity was reduced in CADASIL (33.4±2.7% versus 45.3±3.0%; P<0.01). This difference remained significant when only nondisabled CADASIL individuals (Rankin=0, n=21) were included in the analysis (P<0.05). CO2 reactivity was significantly lower in disabled than in nondisabled CADASIL individuals (24.5±2.7% versus 36.8±3.4%; P<0.05). MCA MFV was reduced in CADASIL (45.6±2.2 cm/s versus 54.2±2.4 cm/s; P<0.05) and correlated negatively with age both in affected individuals (r=-0.314; P<0.05) and control subjects (r=-0.339; P<0.05). Resistance index was not significantly altered (59.0±1.0% versus 57.7±1.2%; P=0.42).
ConclusionsIn CADASIL, there is a reduction of both CO2 reactivity and basal MCA MFV. The reduced CO2 reactivity suggests functional impairment of cerebral vasoreactivity probably related to vascular smooth muscle cell dysfunction. The reduction of CO2 reactivity in nondisabled CADASIL individuals suggests an early role of impaired cerebral vasoreactivity in the evolution of the disease.
Key Words: CADASIL carbon dioxide ultrasonography, Doppler, transcranial
This article has been cited by other articles:
![]() |
Y. Yamamoto, M. Ihara, C. Tham, R. W.C. Low, J. Y. Slade, T. Moss, A. E. Oakley, T. Polvikoski, and R. N. Kalaria Neuropathological Correlates of Temporal Pole White Matter Hyperintensities in CADASIL Stroke, June 1, 2009; 40(6): 2004 - 2011. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.M. Pollock, A.R. Deibler, C.T. Whitlow, H. Tan, R.A. Kraft, J.H. Burdette, and J.A. Maldjian Hypercapnia-Induced Cerebral Hyperperfusion: An Underrecognized Clinical Entity AJNR Am. J. Neuroradiol., February 1, 2009; 30(2): 378 - 385. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Stenborg, H. Kalimo, M. Viitanen, A. Terent, and L. Lind Impaired Endothelial Function of Forearm Resistance Arteries in CADASIL Patients Stroke, October 1, 2007; 38(10): 2692 - 2697. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Viswanathan, J.-P. Guichard, A. Gschwendtner, F. Buffon, R. Cumurcuic, C. Boutron, E. Vicaut, M. Holtmannspotter, C. Pachai, M.-G. Bousser, et al. Blood pressure and haemoglobin A1c are associated with microhaemorrhage in CADASIL: a two-centre cohort study Brain, September 1, 2006; 129(9): 2375 - 2383. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Lacombe, C. Oligo, V. Domenga, E. Tournier-Lasserve, and A. Joutel Impaired Cerebral Vasoreactivity in a Transgenic Mouse Model of Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy Arteriopathy Stroke, May 1, 2005; 36(5): 1053 - 1058. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Dubroca, P. Lacombe, V. Domenga, J. Maciazek, B. Levy, E. Tournier-Lasserve, A. Joutel, and D. Henrion Impaired Vascular Mechanotransduction in a Transgenic Mouse Model of CADASIL Arteriopathy Stroke, January 1, 2005; 36(1): 113 - 117. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Singhal, S. Bevan, T. Barrick, P. Rich, and H. S. Markus The influence of genetic and cardiovascular risk factors on the CADASIL phenotype Brain, September 1, 2004; 127(9): 2031 - 2038. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. B. Hussain, S. Singhal, H. S. Markus, and D. R.J. Singer Abnormal Vasoconstrictor Responses to Angiotensin II and Noradrenaline in Isolated Small Arteries From Patients With Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy (CADASIL) Stroke, April 1, 2004; 35(4): 853 - 858. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. H. Dieu and F. Veyckemans Perioperative management of a CADASIL type arteriopathy patient Br. J. Anaesth., September 1, 2003; 91(3): 442 - 444. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Tatsch, W. Koch, R. Linke, G. Poepperl, N. Peters, M. Holtmannspoetter, and M. Dichgans Cortical Hypometabolism and Crossed Cerebellar Diaschisis Suggest Subcortically Induced Disconnection in CADASIL: An 18F-FDG PET Study J. Nucl. Med., June 1, 2003; 44(6): 862 - 869. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Zimmermann and R.L. Haberl L-Arginine Improves Diminished Cerebral CO2 Reactivity in Patients Stroke, March 1, 2003; 34(3): 643 - 647. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. T. Engelter, S. Rueegg, E. C. Kirsch, F. Fluri, A. Probst, A. J. Steck, and P. A. Lyrer CADASIL Mimicking Primary Angiitis of the Central Nervous System Arch Neurol, September 1, 2002; 59(9): 1480 - 1483. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Liebetrau, J. Herzog, C. U.A. Kloss, G. F. Hamann, and M. Dichgans Prolonged Cerebral Transit Time in CADASIL: A Transcranial Ultrasound Study Stroke, February 1, 2002; 33(2): 509 - 512. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. M. Forteza, B. Brozman, A. A. Rabinstein, J. G. Romano, and W. G. Bradley Acetazolamide for the treatment of migraine with aura in CADASIL Neurology, December 11, 2001; 57(11): 2144 - 2145. [Full Text] [PDF] |
||||
|
Stroke Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2001 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |